Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CSTL
- Price
- 33.42
- Stock movement up
- +0.27 (0.81%)
- Company name
- Castle Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Diagnostics & Research
- Market cap
- 975.48M
- Ent value
- 966.44M
- Price/Sales
- 2.83
- Price/Book
- 2.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.93%
- 1 year return (CAGR)
- 21.04%
- 3 year return (CAGR)
- 8.34%
- 5 year return (CAGR)
- -19.25%
- 10 year return (CAGR)
- -
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CSTL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 15.16 |
| Price to FCF | 34.44 |
| Price to EBITDA | 86.18 |
| EV to EBITDA | 85.38 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.83 |
| Price to Book | 2.07 |
| EV to Sales | 2.81 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 29.19M |
| EPS (TTM) | -0.82 |
| FCF per share (TTM) | 0.97 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 344.23M |
| Gross profit (TTM) | 236.35M |
| Operating income (TTM) | -42.81M |
| Net income (TTM) | -24.16M |
| EPS (TTM) | -0.82 |
| EPS (1y forward) | -0.54 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 68.66% |
| Operating margin (TTM) | -12.44% |
| Profit margin (TTM) | -7.02% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 116.73M |
| Net receivables | 43.38M |
| Total current assets | 361.10M |
| Goodwill | 99.57M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 578.56M |
| Accounts payable | 18.71M |
| Short/Current long term debt | 36.91M |
| Total current liabilities | 68.68M |
| Total liabilities | 107.68M |
| Shareholder's equity | 470.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 64.35M |
| Capital expenditures (TTM) | 36.02M |
| Free cash flow (TTM) | 28.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -5.13% |
| Return on Assets | -4.18% |
| Return on Invested Capital | -5.11% |
| Cash Return on Invested Capital | 5.99% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 33.13 |
| Daily high | 34.18 |
| Daily low | 32.70 |
| Daily Volume | 231K |
| All-time high | 97.33 |
| 1y analyst estimate | 48.50 |
| Beta | 1.13 |
| EPS (TTM) | -0.82 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| CSTL | S&P500 | |
| Current price drop from All-time high | -65.66% | -1.82% |
| Highest price drop | -88.02% | -56.47% |
| Date of highest drop | 5 Jun 2023 | 9 Mar 2009 |
| Avg drop from high | -53.73% | -10.84% |
| Avg time to new high | 28 days | 12 days |
| Max time to new high | 1261 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
975.48M
Marketcap category
Small-cap
Description
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Employees
883
Investor relations
SEC filings
CEO
Derek J. Maetzold
Country
USA
City
Friendswood
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page